4.3 Article

The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML)

期刊

LEUKEMIA RESEARCH
卷 38, 期 10, 页码 1184-1190

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2014.06.018

关键词

Leukemia; Polypharmacy; Medications; Elderly; Older; Mortality

资金

  1. Doug Coley Foundation
  2. American Society of Hematology
  3. Atlantic Philanthropies
  4. John A. Hartford Foundation
  5. Association of Specialty Professors
  6. Paul Beeson Career Development Award in Aging Research [K23AG038361]
  7. NIA
  8. AFAR
  9. Gabrielle's Angel Foundation for Cancer Research

向作者/读者索取更多资源

We retrospectively evaluated the prognostic significance of polypharmacy and inappropriate medication use among 150 patients >60 years of age receiving induction chemotherapy for acute myelogenous leukemia (AML). After adjustment for age and comorbidity, increased number of medications at diagnosis (>= 4 versus <= 1) was associated with increased 30-day mortality (OR=9.98, 95% CI=1.18-84.13), lower odds of complete remission status (OR=0.20, 95% CI=0.06-0.65), and higher overall mortality (HR=2.13, 95% CI=1.15-3.92). Inappropriate medication use (classified according to Beers criteria) was not significantly associated with clinical outcomes. Polypharmacy warrants further study as a modifiable marker of vulnerability among older adults with AML. (C) 2014 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据